29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis

Epidemiology & Clinical Anatomy of Rhinosinusitis

Acute rhinosinusitis is defined as symptomatic inflammation of the mucosal lining of the nasal cavity and paranasal sinuses lasting fewer than 4 weeks. Because the mucous membranes of the paranasal sinuses are continuous with the respiratory epithelium of the nasal passages, pure sinusitis without concurrent rhinitis virtually never occurs; hence, the term rhinosinusitis is preferred in clinical practice and clinical guidelines.

Rhinosinusitis is one of the leading diagnoses in ambulatory family medicine, responsible for more than 20 million outpatient visits and upwards of 15% to 20% of all adult antibiotic prescriptions in the United States. However, an immense epidemiological mismatch exists between clinical presentation and antimicrobial prescribing:

• Acute Viral Rhinosinusitis (AVRS): Represents 90% to 98% of all acute rhinosinusitis presentations in adults.
• Acute Bacterial Rhinosinusitis (ABRS): Accounts for only 2% to 10% of adult episodes, typically arising as a secondary bacterial complication following an antecedent viral upper respiratory infection (URI) or allergic inflammation.

Functional Anatomy of the Paranasal Sinuses

The paranasal sinuses comprise four paired, air-filled bony cavities lined with pseudostratified ciliated columnar epithelium: the maxillary, frontal, anterior/posterior ethmoid, and sphenoid sinuses. Normal sinus physiology relies upon three essential pillars: (1) ostial patency, (2) coordinated ciliary apparatus function, and (3) adequate mucus quality and hydration.

The critical anatomical crossroad is the ostiomeatal complex (OMC), located within the middle meatus beneath the middle turbinate. The OMC serves as the shared drainage pathway for the anterior ethmoid air cells, the maxillary sinus (via its natural ostium situated high on its superomedial wall, requiring ciliary transport against gravity), and the frontal sinus (via the frontonasal duct). Because the drainage channels of the OMC are narrow (often 1 to 2 mm in diameter), even modest mucosal edema rapidly produces mechanical ostial occlusion.

                    OSTIOMEATAL COMPLEX DRAINAGE PATHWAY

            [Frontal Sinus]            [Anterior Ethmoid Air Cells]
                   │                                │
                   ▼                                ▼
           (Frontonasal Duct)              (Infundibulum)
                   │                                │
                   └───────────────┬────────────────┘
                                   ▼
                          [MIDDLE MEATUS / OMC]
                                   ▲
                                   │
                         (Maxillary Sinus Ostium)
                                   │
                          [Maxillary Sinus]

   *Ostial caliber <=1-2 mm: Minimal mucosal edema causes mechanical obstruction,
    hypoxia, impaired ciliary clearance, mucus stasis, and secondary bacterial growth.

---

Pathophysiology of Sinus Obstruction & Secondary Infection

1. Viral Inoculation & Mucosal Injury: Respiratory viruses (predominantly rhinovirus, coronavirus, influenza, parainfluenza, and respiratory syncytial virus [RSV]) bind to respiratory epithelial cells, triggering inflammatory mediator release (interleukin-1, IL-6, IL-8, and tumor necrosis factor-alpha). This cascade produces extensive mucosal hyperemia, intercellular edema, and transudative fluid production.
2. Ciliary Dysfunction & Ostial Occlusion: Viral cytopathology causes shedding of ciliated epithelial cells and transient ciliary dyskinesia. Mucosal tumescence within the narrow ostiomeatal channels obstructs sinus outflow.
3. Intrasinus Stasis & Hypoxia: Trapped intrasinus secretions suffer progressive oxygen absorption, resulting in profound sinus cavity hypoxia and acidosis. This hostile microenvironment paralyzes remaining ciliary beat frequency and promotes secondary bacterial adherence.
4. Secondary Bacterial Overgrowth (ABRS): When transient nasopharyngeal commensals enter the obstructed, stagnant sinus cavity, bacterial proliferation accelerates. The primary pathogens implicated in adult ABRS are:
   • Streptococcus pneumoniae (30% to 35%): Gram-positive diplococci; historically dominant, though intermediate and high-level penicillin resistance mediated by altered penicillin-binding proteins (PBPs) remains a critical therapeutic concern.
   • Haemophilus influenzae (non-typeable, 30% to 35%): Gram-negative coccobacilli; increased in prevalence following widespread pneumococcal conjugate vaccination. Approximately 30% to 40% of strains produce beta-lactamase.
   • Moraxella catarrhalis (10% to 15%): Gram-negative diplococci; >90% to 95% produce beta-lactamase.
   • Staphylococcus aureus and anaerobic organisms (Peptostreptococcus, Prevotella, Fusobacterium): Infrequently encountered in acute community-acquired ABRS, but prominent in odontogenic maxillary sinusitis, which accounts for approximately 10% to 15% of unilateral maxillary sinusitis cases secondary to periapical dental abscesses or periodontal disease involving the maxillary premolars or molars.

---

Clinical Differentiation: The Three Cardinal Diagnostic Patterns

Because viral and bacterial rhinosinusitis share nearly identical initial symptoms—including nasal congestion, purulent rhinorrhea, facial pain/pressure, maxillary dental ache, postnasal drip, headache, and fatigue—clinical differentiation cannot rely upon symptom characteristics alone.

[!IMPORTANT] Purulent (thick, discolored, green or yellow) nasal discharge does NOT indicate bacterial infection! In viral colds, the influx and lysis of neutrophils with enzymatic release of myeloperoxidase naturally turns nasal secretions opaque and greenish-yellow on days 2 to 4 of illness.

To prevent gross overprescribing of antibiotics, the Infectious Diseases Society of America (IDSA) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) have established three rigorous clinical patterns that define Acute Bacterial Rhinosinusitis (ABRS):

               IDSA / AAO-HNS DIAGNOSTIC CRITERIA FOR ABRS

   ┌─────────────────────────────────────────────────────────────────────────┐
   │  Pattern 1: PERSISTENT SIGNS & SYMPTOMS (>=10 Days)                     │
   │  • Nasal discharge, congestion, or facial pain lasting >=10 days       │
   │  • NO evidence of clinical improvement whatsoever                       │
   ├─────────────────────────────────────────────────────────────────────────┤
   │  Pattern 2: SEVERE ONSET (>=3-4 Consecutive Days)                       │
   │  • High fever (>=39.0°C / 102.2°F)                                      │
   │  • Purulent nasal discharge AND/OR severe focal facial pain             │
   │  • Present concurrently for >=3-4 consecutive days at illness onset     │
   ├─────────────────────────────────────────────────────────────────────────┤
   │  Pattern 3: 'DOUBLE SICKENING' (Biphasic Course)                        │
   │  • Typical viral URI that begins to improve or resolve after 3-5 days   │
   │  • Sudden acute recrudescence with new fever, severe headache,          │
   │    increased facial pain, or worsening purulent rhinorrhea on days 5-8  │
   └─────────────────────────────────────────────────────────────────────────┘

1. Persistent Symptoms (>=10 Days)

Viral upper respiratory infections typically peak in severity between days 3 and 5 and progressively resolve within 7 to 10 days. Therefore, signs and symptoms of acute rhinosinusitis (nasal obstruction, anterior/posterior purulent drainage, facial pressure/pain) that persist for 10 or more days without any subjective or objective clinical improvement indicate secondary bacterial infection.

2. Severe Symptoms at Onset (>=3-4 Consecutive Days)

Unlike typical viral colds that present with low-grade fever and mild malaise, ABRS may manifest as an aggressive acute infection. Severe presentation requires high fever (temperature >=39.0°C or 102.2°F) accompanied by purulent nasal discharge or focal unilateral facial pain for at least 3 to 4 consecutive days at the start of illness.

3. 'Double Sickening' (Biphasic Illness)

This hallmark pattern reflects an initial uncomplicated viral rhinosinusitis that begins to improve after 3 to 5 days, followed by acute secondary deterioration between days 5 and 8. Patients report sudden onset of new or higher fever, severe unremitting headache, intensifying unilateral maxillary or frontal facial pain, or dramatic escalation of purulent nasal secretions.

---

The Choosing Wisely Campaign & Antibiotic Stewardship

The American Board of Internal Medicine (ABIM) Foundation and the American Academy of Family Physicians (AAFP) under the Choosing Wisely campaign provide unambiguous recommendations regarding acute rhinosinusitis:

1. Avoid Routine Radiologic Imaging: Plain sinus radiographs (Waters, Caldwell, lateral views) have unacceptably low sensitivity and specificity and must not be performed. Even non-contrast paranasal sinus CT scans show mucosal thickening, air-fluid levels, and sinus opacification in over 80% to 90% of patients with uncomplicated viral colds. Routine CT imaging leads to unnecessary ionizing radiation exposure, excessive financial cost, and spurious diagnostic confirmation that drives inappropriate antibiotic use. CT imaging is strictly reserved for suspected orbital or intracranial complications.
2. Avoid Routine Antibiotic Therapy for Uncomplicated Sinusitis <10 Days: Because >90% of rhinosinusitis cases are viral, prescribing antibiotics before day 10 exposes patients to adverse drug reactions (severe diarrhea, Clostridioides difficile colitis, cutaneous eruptions, anaphylaxis) without clinical benefit.
3. Natural History & The Option for Watchful Waiting: Even among patients who strictly fulfill the 10-day diagnostic criteria for ABRS, approximately 60% to 75% achieve spontaneous clinical cure within 7 to 14 days through endogenous immune clearance. The AAO-HNS guidelines recommend offering watchful waiting (initial observation for up to 7 days) to reliable adult patients with mild-to-moderate ABRS who have ready access to follow-up care, utilizing delayed ('safety-net') antibiotic prescriptions if symptoms fail to improve.

---

Evidence-Based Antimicrobial Pharmacotherapy

When antibiotic therapy is indicated for ABRS, antimicrobial selection must account for the high prevalence of beta-lactamase-producing H. influenzae and M. catarrhalis, alongside penicillin-resistant S. pneumoniae (PRSP).

                 ABRS ANTIMICROBIAL SELECTION ALGORITHM

                     Confirmed ABRS (Meets 1 of 3 Criteria)
                                       │
                                       ▼
                         Penicillin Allergy Assessment
                                       │
                ┌──────────────────────┴──────────────────────┐
                ▼                                             ▼
        NO ALLERGY                                   TRUE PENICILLIN ALLERGY
                │                                             │
        High-Risk Features?*                          ┌───────┴───────┐
        ┌───────┴───────┐                             ▼               ▼
        ▼               ▼                        Doxycycline    Levofloxacin
       NO              YES                       100 mg BID     500 mg Daily
Standard Dose      High-Dose                     x 5-7 Days     x 5-7 Days
Amox-Clav          Amox-Clav                     (Preferred)   (Severe/Failed)
875/125 mg BID     2,000/125 mg BID
x 5-7 Days         x 7-10 Days

   *High-risk features: Age >=65y, prior abx in past 30 days, recent hospitalization,
    immunocompromised state, severe systemic toxicity (T >=39°C), or PRSP rate >=10%.

First-Line Regimen: Standard-Dose Amoxicillin-Clavulanate

• Regimen: Amoxicillin-clavulanate (Augmentin) 875/125 mg PO BID for 5 to 7 days in adults.
• Why not amoxicillin monotherapy? Amoxicillin alone provides excellent coverage against S. pneumoniae, but lacks stability against the beta-lactamases produced by 30% to 40% of non-typeable H. influenzae and >90% of M. catarrhalis. The addition of the beta-lactamase inhibitor clavulanate restores full activity.
• Duration: Randomized trials demonstrate that a 5- to 7-day course is therapeutically equivalent to traditional 10- to 14-day courses in uncomplicated adult ABRS, while substantially reducing gastrointestinal side effects and selective pressure for resistance.

High-Dose Amoxicillin-Clavulanate Regimen

• Regimen: Amoxicillin-clavulanate 2,000/125 mg extended-release PO BID for 7 to 10 days (or standard amoxicillin-clavulanate supplemented with pure amoxicillin to deliver 2,000 mg amoxicillin BID with 125 mg clavulanate BID).
• Indications for High-Dose Augmentin:
  1. Age >=65 years;
  2. Systemic antibiotic exposure within the preceding 30 days;
  3. Hospitalization within the past 5 days;
  4. Immunocompromised host (diabetes mellitus, chronic kidney disease, active immunosuppression);
  5. Severe infection (fever >=39.0°C, systemic toxicity, severe unilateral facial pain);
  6. High local endemic prevalence of penicillin-non-susceptible S. pneumoniae (>=10%).

Penicillin-Allergic Regimens

In patients with a documented, convincing penicillin allergy:

1. First-Line Penicillin-Allergic Choice: Doxycycline 100 mg PO BID for 5 to 7 days.
   • Doxycycline demonstrates excellent in vitro activity against S. pneumoniae, non-typeable H. influenzae, and M. catarrhalis.
   • It exhibits low resistance rates, minimal risk of selecting for multi-drug resistant pathogens, and favorable cost and tolerability profiles.
2. Respiratory Fluoroquinolones: Levofloxacin 500 mg PO once daily OR Moxifloxacin 400 mg PO once daily for 5 to 7 days.
   • Reserved for patients who cannot tolerate doxycycline, those with high-risk features, or those failing initial therapy.
   • Fluoroquinolones carry FDA black-box warnings for tendinitis, tendon rupture (Achilles tendon), peripheral neuropathy, central nervous system toxicities, aortic dissection, and QT interval prolongation.

[!CAUTION] Antimicrobial Regimens to Strictly Avoid in ABRS:

• Macrolides (Azithromycin, Clarithromycin): Upwards of 30% to 40% of S. pneumoniae isolates in North America possess macrolide resistance (mediated by mefA efflux pumps or ermB ribosomal methylation). The ubiquitous 'Z-pack' must NEVER be prescribed for ABRS.
• Trimethoprim-Sulfamethoxazole (TMP-SMX): Resistance rates among S. pneumoniae and H. influenzae exceed 30% to 50%.
• Oral Cephalosporin Monotherapy: First-generation cephalosporins (cephalexin) lack activity against H. influenzae. Second- and third-generation oral cephalosporins (cefdinir, cefuroxime axetil, cefpodoxime) have variable pneumococcal coverage and should not be used as monotherapy unless combined with clindamycin.

---

Symptomatic Management & The Danger of Rhinitis Medicamentosa

Symptomatic and adjunctive therapies should be offered to all patients with acute rhinosinusitis, whether viral or bacterial:

1. Intranasal Saline Irrigation: Large-volume, low-pressure saline rinses (using isotonic or hypertonic sterile/distilled water delivered via neti pot or squeeze bottle) mechanically flush inspissated mucus, reduce mucosal edema, liquefy crusted secretions, and facilitate mucociliary transport. Highly recommended as an adjunct by both IDSA and AAO-HNS.
2. Intranasal Corticosteroids (INCS): Fluticasone propionate (2 sprays per nostril daily) or mometasone furoate (2 sprays per nostril daily) suppresses local mucosal cytokines, decreases ostiomeatal inflammation, and accelerates ostial reopening. Particularly beneficial in individuals with underlying allergic rhinitis or chronic rhinosinusitis.
3. Analgesics and Antipyretics: Acetaminophen (500 to 1,000 mg every 6 hours as needed, max 3,000 to 4,000 mg/day) and ibuprofen (400 to 600 mg every 6 to 8 hours with meals) effectively control facial pain, pressure, and fever.
4. Oral Decongestants (Pseudoephedrine): Provides modest subjective decongestion via alpha-adrenergic vasoconstriction of capacitance vessels. Caution is warranted in patients with systemic arterial hypertension, arrhythmias, closed-angle glaucoma, and benign prostatic hyperplasia.
5. Oral Antihistamines: Strictly NOT recommended in non-allergic acute rhinosinusitis. Anticholinergic drying effects thicken intrasinus secretions and impair ciliary clearance, worsening sinus outflow obstruction.

The Critical Warning: Oxymetazoline & Rhinitis Medicamentosa

Topical intranasal vasoconstrictor sprays such as oxymetazoline 0.05% (Afrin) act directly on post-junctional alpha-1 and alpha-2 adrenergic receptors on nasal capacitance venules, producing rapid and profound mucosal decongestion within minutes.

• The Rule of 3 to 5 Days: Oxymetazoline use must be strictly restricted to no more than 3 to 5 consecutive days.
• Pathophysiology of Rhinitis Medicamentosa: Prolonged continuous stimulation of alpha-adrenergic receptors triggers rapid receptor down-regulation, desensitization, and tachyphylaxis. Concurrently, local ischemia and rebound endogenous beta-receptor-mediated vasodilation ensue. Upon medication cessation, the patient suffers severe, intractable rebound chemical vasodilatation, intense interstitial edema, and severe nasal obstruction.
• Clinical Presentation: The patient presents with complete, relentless nasal obstruction that is refractory to standard decongestants, accompanied by dry, hyperemic, 'beefy-red' hypertrophic nasal mucosa. Patients enter an addiction-like cycle of spraying oxymetazoline every 2 to 3 hours just to breathe.
• Treatment of Rhinitis Medicamentosa: Immediate and complete cessation of the topical decongestant. To manage severe rebound obstruction during withdrawal, initiate high-dose intranasal corticosteroids (e.g., fluticasone 2 sprays each nostril BID), aggressive saline irrigations, and in severe cases, a short tapering course of oral corticosteroids (prednisone 30 to 40 mg daily tapered over 5 to 7 days).

---

Sight- and Life-Threatening Complications: Orbital & Intracranial Red Flags

The paranasal sinuses share intimate anatomical relationships with the orbits and the intracranial vault, separated only by thin bony partitions and valve-less diploic veins (veins of Breschet):

• The ethmoid sinus is separated from the orbit by the paper-thin lamina papyracea; ethmoiditis is the primary source of pediatric and adult orbital complications.
• The frontal sinus posterior table abuts the anterior cranial fossa; frontal sinusitis can breach the bone to form a subperiosteal abscess of the frontal bone (Pott's puffy tumor) or extend intracranially.
• The sphenoid sinus is enveloped by the cavernous sinuses, internal carotid arteries, and cranial nerves III, IV, V1, V2, and VI.

                 RED FLAGS IN ACUTE RHINOSINUSITIS

     ORBITAL COMPLICATIONS                 INTRACRANIAL COMPLICATIONS
  • Axial Proptosis                     • Severe, Unremitting Frontal Headache
  • Pain with Extraocular Motion        • Altered Mental Status / Lethargy
  • Diplopia (Gaze Limitation)          • High Spiking Fevers with Rigors
  • Decreased Visual Acuity             • Meningismus (Nuchal Rigidity)
  • Afferent Pupillary Defect           • Focal Neurological Deficits / Seizures
  • Marked Periorbital Chemosis         • Bilateral Orbital Signs (Cavernous Sinus)
                      │                               │
                      └───────────────┬───────────────┘
                                      ▼
                  EMERGENCY INTERVENTIONS (MANDATORY)
                  1. STAT Contrast-Enhanced CT / MRI of Orbits & Sinuses
                  2. Emergent ENT & Ophthalmology Consultation
                  3. Hospital Admission for IV Broad-Spectrum Antibiotics
                     (Vancomycin + Ceftriaxone + Metronidazole)
                  4. Emergent Surgical Drainage if Abscess / Vision Loss

Chandler Classification of Orbital Complications

Orbital extension of acute rhinosinusitis progresses through five distinct pathological stages defined by Chandler:

---

High-Yield Board Pearls: Acute Rhinosinusitis

• The 10-Day Rule: Never prescribe antibiotics for uncomplicated sinus symptoms present for fewer than 10 days unless the patient displays severe onset (T >=39°C + purulence/pain for >=3-4 consecutive days) or 'double sickening'.
• Macrolide Myth: Macrolides (azithromycin) are completely inappropriate for ABRS due to 30% to 40% pneumococcal resistance. A patient demanding a 'Z-pack' for acute sinusitis must be redirected.
• Odontogenic Origin: A patient presenting with unilateral, foul-smelling maxillary sinus discharge with facial pressure must have their maxillary dentition evaluated; up to 15% of maxillary sinusitis arises from periapical molar infections requiring dental extraction or root canal along with anaerobic coverage.
• Oxymetazoline Limitation: Limit topical oxymetazoline to <=3 to 5 days to prevent rhinitis medicamentosa. When present, treat with cessation of oxymetazoline, high-dose intranasal corticosteroids, and an oral steroid taper.
• Pott's Puffy Tumor: A fluctuant, doughy swelling on the forehead with fever indicates subperiosteal abscess of the frontal bone secondary to frontal osteomyelitis, requiring emergent imaging and intravenous antibiotics.
• Vision Loss is a Surgical Emergency: Any decrease in visual acuity or appearance of an afferent pupillary defect in a patient with sinusitis signifies impending optic nerve ischemia from orbital apex compression, requiring emergent surgical decompression.